Jean-Michel Hannoun-Lévi1, Daniel Lam Cham Kee2, Jocelyn Gal3, Renaud Schiappa3, Arthur Hannoun4, Mathieu Gautier2, Rabia Boulahssass5, Isabelle Peyrottes6, Emmanuel Barranger7, Jean-Marc Ferrero8, Marie-Eve Chand2, Jérôme Doyen2. 1. Department of Radiation Oncology, Antoine Lacassagne Cancer Center, University of Cote d'Azur, Nice, France. Electronic address: jean-michel.hannoun-levi@nice.unicancer.fr. 2. Department of Radiation Oncology, Antoine Lacassagne Cancer Center, University of Cote d'Azur, Nice, France. 3. Biostatistic Unit, Antoine Lacassagne Cancer Center, University of Cote d'Azur, Nice, France. 4. Lycée Massena, University of Cote d'Azur, Nice, France. 5. Geriatric Unit, CHU de NICE, FHU ONCOAGE, University of Cote d'Azur, Nice, France. 6. Department of Pathology, Antoine Lacassagne Cancer Center, University of Cote d'Azur, Nice, France. 7. Department of Breast Surgery, Antoine Lacassagne Cancer Center, University of Cote d'Azur, Nice, France. 8. Department of Medical Oncology, Antoine Lacassagne Cancer Center, University of Cote d'Azur, Nice, France.
Abstract
PURPOSE/ OBJECTIVE: To evaluate feasibility and early clinical outcomes of a single fraction of multi-catheter interstitial high-dose rate brachytherapy for accelerated partial breast irradiation (APBI) in the elderly. MATERIAL/ METHODS: From November 2012 to September 2014, 26 patients (≥70) with early breast cancer were enrolled in a prospective phase II trial (NCT01727011). After lumpectomy, intra-operative catheter implant was performed for post-operative APBI (single fraction 16 Gy). Surveillance was achieved at 1, 3 and 6 months after APBI, then twice a year. Acute toxicity was investigated. Early cosmetic outcome was analyzed (patient, radiation oncologist, 2 observers). Local and regional relapse-free survival, cancer specific survival and overall survival were analyzed. RESULTS: Median age was 77 years [69-89]. Median CTV was 41 cc [22-95]. Acute toxicity was observed in 18 pts (70%) with a total of 44 events: G1: 75.7%; G2: 22.8%; G3: 4.5%. Breast fibrosis (31.8%), puncture site inflammation (13.6%) and skin hyperpigmentation (11.4%) were the most frequent side effects. Cosmetic evaluation at 6 months was excellent/good in 88%, 92%, 85% and 88% for patient, radiation oncologist, observer #1 and #2 respectively. With a median follow-up of 37.2 months [35.6-42.3], side effects were G1: 4 pts (15%) and G2: 1 pt (4%). Three-year Local and regional relapse-free survival, cancer specific survival and overall survival rates were 100%, 100%, 100% and 95.2% respectively. CONCLUSIONS: For elderly early breast cancer, a post-operative multi-catheter interstitial high-dose rate brachytherapy single dose (16 Gy) appears feasible. Acute toxicity is acceptable as well as early cosmetic outcome. Oncologic outcome seems encouraging and allows going forward with new clinical trials focusing on single fraction APBI.
PURPOSE/ OBJECTIVE: To evaluate feasibility and early clinical outcomes of a single fraction of multi-catheter interstitial high-dose rate brachytherapy for accelerated partial breast irradiation (APBI) in the elderly. MATERIAL/ METHODS: From November 2012 to September 2014, 26 patients (≥70) with early breast cancer were enrolled in a prospective phase II trial (NCT01727011). After lumpectomy, intra-operative catheter implant was performed for post-operative APBI (single fraction 16 Gy). Surveillance was achieved at 1, 3 and 6 months after APBI, then twice a year. Acute toxicity was investigated. Early cosmetic outcome was analyzed (patient, radiation oncologist, 2 observers). Local and regional relapse-free survival, cancer specific survival and overall survival were analyzed. RESULTS: Median age was 77 years [69-89]. Median CTV was 41 cc [22-95]. Acute toxicity was observed in 18 pts (70%) with a total of 44 events: G1: 75.7%; G2: 22.8%; G3: 4.5%. Breast fibrosis (31.8%), puncture site inflammation (13.6%) and skin hyperpigmentation (11.4%) were the most frequent side effects. Cosmetic evaluation at 6 months was excellent/good in 88%, 92%, 85% and 88% for patient, radiation oncologist, observer #1 and #2 respectively. With a median follow-up of 37.2 months [35.6-42.3], side effects were G1: 4 pts (15%) and G2: 1 pt (4%). Three-year Local and regional relapse-free survival, cancer specific survival and overall survival rates were 100%, 100%, 100% and 95.2% respectively. CONCLUSIONS: For elderly early breast cancer, a post-operative multi-catheter interstitial high-dose rate brachytherapy single dose (16 Gy) appears feasible. Acute toxicity is acceptable as well as early cosmetic outcome. Oncologic outcome seems encouraging and allows going forward with new clinical trials focusing on single fraction APBI.
Authors: Colleen F Longacre; Hannah T Neprash; Nathan D Shippee; Todd M Tuttle; Beth A Virnig Journal: Womens Health Rep (New Rochelle) Date: 2021-01-11
Authors: Javier Anchuelo Latorre; Piedad Galdós; Lucía Alonso Buznego; Ana García Blanco; Juan Cardenal; María Ferri; Iván Díaz de Cerio; Elisabet Arrojo; Nicolás Sierrasesúmaga; Mónica González Noriega; Ana De Juan Ferré; Rosa Fabregat; Samuel Ruíz; Pedro J Prada Journal: J Contemp Brachytherapy Date: 2018-02-28
Authors: Nam P Nguyen; Ulf Karlsson; Eromosele Oboite; Julio Alvarenga; Juan Godinez; Alice Zamagni; Micaela Motta; Satya Bose; Vincent Vinh-Hung Journal: Transl Cancer Res Date: 2020-01 Impact factor: 1.241
Authors: Igor Sirák; Miroslav Hodek; Pavel Jandík; Jakub Grepl; Petr Paluska; Jiří Petera Journal: Transl Cancer Res Date: 2020-01 Impact factor: 1.241